Open AccessPooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Author(s) -
Inder Paul Singh,
Robert D. Fechtner,
Jonathan S. Myers,
Terry Kim,
Dale W. Usner,
Hayley McKee,
Huan Sheng,
Richard A. Lewis,
Theresa Heah,
Casey Kopczynski
Publication year - 2020
Publication title -
journal of glaucoma
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.11
H-Index - 88
eISSN - 1536-481X
pISSN - 1057-0829
DOI - 10.1097/ijg.0000000000001634
Subject(s) - timolol , medicine , ocular hypertension , intraocular pressure , adverse effect , glaucoma , population , ophthalmology , anesthesia , environmental health
In pooled phase III analyses, once-daily netarsudil 0.02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0.5%, with minimal treatment-related serious or systemic adverse events (AEs). Ocular AEs were generally tolerable.